Eli Lilly's acquisition of Centessa Pharma and Biogen's takeover of Apellis Pharma led to a 7% surge in the XBI index on the last day of Q1, salvaging what was previously heading towards a quarterly loss. This spate of mergers and acquisitions signals continued investor interest in biotech, offering developers and tech professionals opportunities in integration technologies and data analytics. Watch for further M&A activities as they could drive stock performance and innovation in the sector.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



